Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

The CD5CAR design is comprised of anti-CD5 scFv, a CD8-derived hinge (H) and transmembrane region, and CD28 and 4-1BB intracellular signaling domains in tandem with the CD3 zeta signaling domain ...

The case illustrations demonstrate a wide spectrum of presentation, imaging results and treatment strategies. Debate will continue as to whether lymphocytic hypophysitis is in fact a type of ...

As East Asia prepares to shut down for the Lunar New Year holiday and looks towards the Year of the Snake, it’s time to look back at bitcoin (BTC) and the CoinDesk 20 (CD20)’s performance ...

PK/PD analyses of circulating tumor DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC) treated with telisotuzumab adizutecan (ABBV-400). This is an ASCO Meeting Abstract from the 2025 ...

Today, a brief rundown of news involving Intellia Therapeutics and ArriVent BioPharma, as well as updates from Atara Biotherapeutics, Amylyx Pharmaceuticals and InnoCare Pharma that you may have ...

ICP-B02 binds to CD20 on the tumour cells and CD3 on the T cells, redirects and activates T cells to eradicate tumour cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...

In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...